Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy.

Front Public Health · 2025 · PMC12081414 · PMID 40385627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In China, there is an increasing trend towards the standardizing access negotiations for anticancer drugs within medical insurance frameworks, which is expected to become the primary pathway for incorporating innovative drugs into the medical insurance system.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.